Avectas Revenue and Competitors
Estimated Revenue & Valuation
- Avectas's estimated annual revenue is currently $4.6M per year.
- Avectas's estimated revenue per employee is $77,500
- Avectas's total funding is $38.9M.
Employee Data
- Avectas has 59 Employees.
- Avectas grew their employee count by 13% last year.
Avectas's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Business Development | Reveal Email/Phone |
3 | Director Process Engineering | Reveal Email/Phone |
4 | Founder & Director, CSO | Reveal Email/Phone |
5 | Senior Director Process & Analytical Development | Reveal Email/Phone |
6 | Senior Director, Finance and Strategic Operations | Reveal Email/Phone |
7 | Senior Director Project and Vendor Management | Reveal Email/Phone |
8 | Associate Director, Finance | Reveal Email/Phone |
9 | Chief Business Officer | Reveal Email/Phone |
10 | Senior Director Quality Regulatory and Supply Chain | Reveal Email/Phone |
Avectas Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Avectas?
Avectas is a cell engineering business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique delivery technology platform, Solupore®, to enable the ex-vivo manufacture of gene modified cell therapy products, with partners. Solupore® is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality. The Solupore® technology is designed for use with mRNA, DNA, and proteins, including gene editing tools such as CRISPR. Solupore® achieves excellent engineering efficiencies for delivery of these payloads to primary T cells and NK cells for immuno-oncology and gene editing applications. Avectas is currently developing the clinical (cGMP) technology embodiment while enhancing its dataset, implementing its commercialization strategy and building out the team.
keywords:N/A
$38.9M
Total Funding
59
Number of Employees
$4.6M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Avectas News
DUBLIN, April 22, 2021 /PRNewswire/ -- Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government's Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary ...
Avectas, an Irish cell engineering technology company, has completed a significant new Series C equity funding of approximately $20m. The round, which brought the total equity invested in the business to date to $40m, was led by existing shareholders, including Seamus Mulligan. The company int ...
Avectas, a Dublin, Ireland- and Cambridge, MA-based cell engineering technology company, completed a US$10m equity financing. The round was led by Seamus Mulligan. The company intends to use the funds to accelerate the development, scale-up and commercialisation of Solupore®. Founded in 2012 ...